论文部分内容阅读
由山东医科大学、昌潍医学院等单位协作研制的人胚胸腺素,经对小儿呼吸道反复感染、小儿支气管哮喘、流行性出血热、带状疱疹、类风湿性关节炎及老年免疫功能低下六种疾病的三百七十七例患者治疗表明,总有效率达到96.02％。于1986年12月该药通过了鉴定。医药用胸腺素制剂过去是从动物胸腺中提取的,它虽能纠正各种免疫功能紊乱性疾病,但有些制剂有一定的过敏性。利用人胚胸腺制得的胸腺素,因没有种属差异,消除了异种蛋白的抗原性,具有活性高、疗效好,费用低廉
By the Shandong Medical University, Chang Wei Medical College and other units of human embryonic development of thymosin, repeated respiratory tract infections in children, children with bronchial asthma, epidemic hemorrhagic fever, shingles, rheumatoid arthritis and senile immune function six The treatment of 377 patients with various diseases showed that the total effective rate reached 96.02%. In December 1986 the drug passed the appraisal. In the past, medicinal thymosin preparations were extracted from animal thymus. Although it can correct various immunological disorders, some preparations have some allergies. Thymosin produced by human embryo thymus, because there is no species differences, eliminating the antigenicity of foreign proteins, with high activity, good curative effect, low cost